Trial · NCT01524848
Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
NCT01524848, Phase 2, Completed, Scandinavian Sarcoma Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib. Trials, record NCT01524848. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01524848
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
- NCT number
- NCT01524848
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 72 participants, estimated
- Lead sponsor
- Scandinavian Sarcoma Group
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Pazopanib
- First posted
- 2012-02-02
- Last updated
- 2017-05-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease control rate | Week 12 | The ratio of patients with CR (complete remission) + PR (partial remission) + SD (stable disease) at week 12 after start of treatment |
| Secondary | Progression free survival (PFS) | The patients will be followed for the duration of the trial treatment, an expected average of 6 months | Progression free survival (KM analysis) for all patients administered the study drug |
| Secondary | DCR in relation to mutation | Week 12 | Disease control rate as described above in relation to the type of mutation of the primary tumor if this is available (not mandatory) |
| Secondary | DCR in relation to plasma concentration | Week 12 | Disease control rate as defined above in relation to the trough level (plasma concentration) of the study drug at week 12 |
| Secondary | Toxicity | The patients will be followed for the duration of the trial treatment + 1 month, an expected average of 7 months | Recording of adverse events including SAE/SAR for all patients administered the study drug |
| Secondary | Overall response rate | The patients will be followed for the duration of the trial treatment, an expected average of 6 months | ORR = CR+PR at the time of best response during the study period |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01524848
GET https://conductscience.org/api/trials/v1/NCT01524848/registered